These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 26320063)

  • 1. Antagonists of PD-1 and PD-L1 in Cancer Treatment.
    Lipson EJ; Forde PM; Hammers HJ; Emens LA; Taube JM; Topalian SL
    Semin Oncol; 2015 Aug; 42(4):587-600. PubMed ID: 26320063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
    Remon J; Chaput N; Planchard D
    Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino L; Botti G; Lorigan P; Masucci GV; Hipp JD; Horak CE; Melero I; Ascierto PA
    Drugs; 2016 Jun; 76(9):925-45. PubMed ID: 27229745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy.
    Sznol M
    Cancer J; 2014; 20(4):290-5. PubMed ID: 25098290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
    Hamid O; Carvajal RD
    Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
    Jørgensen JT
    Expert Rev Mol Diagn; 2016; 16(2):131-3. PubMed ID: 26559787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
    Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
    Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1 inhibitors.
    Sunshine J; Taube JM
    Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for targeting PD-1 and PD-L1 in various tumor types.
    Kim JW; Eder JP
    Oncology (Williston Park); 2014 Nov; 28 Suppl 3():15-28. PubMed ID: 25387682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
    Sacher AG; Gandhi L
    JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction.
    Gettinger S; Herbst RS
    Cancer J; 2014; 20(4):281-9. PubMed ID: 25098289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions.
    Karim S; Leighl N
    Future Oncol; 2016 Jan; 12(1):9-23. PubMed ID: 26631501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
    Kerr KM; Nicolson MC
    Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.
    He J; Hu Y; Hu M; Li B
    Sci Rep; 2015 Aug; 5():13110. PubMed ID: 26279307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive markers for the new immunotherapies.
    Mahoney KM; Atkins MB
    Oncology (Williston Park); 2014 Nov; 28 Suppl 3():39-48. PubMed ID: 25384886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
    Shin DS; Ribas A
    Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
    Chen DS; Irving BA; Hodi FS
    Clin Cancer Res; 2012 Dec; 18(24):6580-7. PubMed ID: 23087408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.